The Maharashtra Food and Drugs Administration (FDA) has seized 13 not-of-standard drugs in the month of November. During its routine random sample testing in November, it was found that manufacturers from Himachal Pradesh accounted for major share with eight not-of-standard drugs.
The not-of-standard drugs manufactured by the leading pharmaceutical companies includes Claris LifeSciences for TNA-PERI Total nutrient admixture from Gujarat, Ankur Drugs & Pharma for Ospamox 125 mg/ 5ml, amoxycillin oral suspension IP, D M Pharma for Rabob, rabeprazole sodium tablets and Ultra Drugs for Altole-D tablets from Himachal Pradesh, Talent Healthcare for Panvom-D, pantoprazole & domperidone tablets from Uttaranchal.
As per latest data released by State FDA, eight were from Himachal Pradesh, three from Gujarat and one each from Uttaranchal and Maharashtra.
Other companies in the not-of-standard drugs list includes: Globela Pharma for Glofen, ibuprofen and paracetamol tablets, Jilichem Laboratories for Becojil B-complex tablets from Gujarat, ION Healthcare for Femax syrup, Japshichem Pharmaceuticals for Verotone, haematinic syrup with proen, folic acid, Preet Remedies for AMIBA-L capsules, SPB Pharma for hydroquinone+tretinoin+momentasone furoate cream from Himachal Pradesh and Nirmay Pharma for Healer 10 tablets from Nashik, Maharashtra.
FDA has now issued note of caution to all hospitals, pharmacy trade and the public to refrain from prescribing, stocking and taking these drugs.